MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
33.37
-1.62
-4.63%
Closed 19:49 05/13 EDT
OPEN
35.00
PREV CLOSE
34.99
HIGH
35.11
LOW
32.68
VOLUME
4.15M
TURNOVER
--
52 WEEK HIGH
46.48
52 WEEK LOW
15.16
MARKET CAP
5.30B
P/E (TTM)
136.82
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TGTX last week (0505-0509)?
Weekly Report · 1d ago
Biotech Outperformance - Can't Take What's Already Earned
Seeking Alpha · 4d ago
SA analyst upgrades: AMD, MPW, LYV, TGTX
Seeking Alpha · 05/06 15:28
J.P. Morgan Remains a Buy on TG Therapeutics (TGTX)
TipRanks · 05/06 12:21
Sell Rating for TG Therapeutics Amidst Growth Concerns and Competitive Challenges
TipRanks · 05/06 09:57
TG Therapeutics Reports Strong Q1 2025 Results
TipRanks · 05/06 04:01
TG Therapeutics’ Earnings Call: Strong Growth and Strategic Advances
TipRanks · 05/06 00:13
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
Benzinga · 05/05 20:37
More
About TGTX
More
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Recently
Symbol
Price
%Change
    CPA
  • 101.90
  • +2.79%

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.